Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Detailed results were announced from a phase 3 clinical trial evaluating the use of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The multicenter, ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...